Artificial Intelligence
Global Digital Pathology Systems Market to Reach US$1.4 Billion by the Year 2027
New York, July 22, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Digital Pathology Systems Industry” – https://www.reportlinker.com/p05205340/?utm_source=GNW
9 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 13.9% over the analysis period 2020-2027.Device, one of the segments analyzed in the report, is projected to grow at a 13.8% CAGR to reach US$753.1 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 14.6% CAGR for the next 7-year period. This segment currently accounts for a 29.2% share of the global Digital Pathology Systems market.
The U.S. Accounts for Over 42.1% of Global Market Size in 2020, While China is Forecast to Grow at a 15.1% CAGR for the Period of 2020-2027
The Digital Pathology Systems market in the U.S. is estimated at US$241.7 Million in the year 2020. The country currently accounts for a 42.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$114.2 Million in the year 2027 trailing a CAGR of 15.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 12.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR while Rest of European market (as defined in the study) will reach US$114.2 Million by the year 2027.
Other Segments Segment Corners a 17.8% Share in 2020
In the global Other Segments segment, USA, Canada, Japan, China and Europe will drive the 12.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$86.6 Million in the year 2020 will reach a projected size of US$200.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$68.5 Million by the year 2027, while Latin America will expand at a 12.5% CAGR through the analysis period.
Select Competitors (Total 74 Featured)
- 3DHISTECH Ltd.
- Apollo Enterprise Imaging Corp.
- Carl Zeiss AG
- Corista LLC
- Glencoe Software, Inc
- Hamamatsu Photonics K.K.
- Huron Digital Pathology, Inc.
- Indica Labs
- Inspirata Inc
- KANTERON SYSTEMS S.L.U
- KONFOONG BIOTECH INTERNATIONAL CO.,LTD
- Leica Biosystems Nussloch GmbH
- MikroScan Technologies
- Inc.
- Objective Pathology Services
- Olympus Corporation
- OptraSCAN, Inc
- Philips Healthcare
- Proscia Inc
- Sectra AB
- Visiopharm A/S
Read the full report: https://www.reportlinker.com/p05205340/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
COVID-19 Ushers in 2020 as the Year of Healthcare Digitalization
EXHIBIT 1: Global Venture Capital Investments in Digital Health
Startups (In US$ Billion)
EXHIBIT 2: % Share VC Investments by Category for 2020
FDA Temporarily Relaxes Guidelines to Promote Remote Digital
Pathology Services amid COVID-19 Pandemic
COVID-19 Highlights Need to Implement Structured Online
Curriculum for Pathology Training
Future Outlook of Pathology Post-COVID-19
Digital Pathology: An Introduction
Key Digital Pathology Tools
Market Outlook
US and Europe Maintain Dominance
Emerging Markets to Experience Strong Growth
Scanners Lead Digital Pathology Market
Software Segment Post Strong Growth
Disease Diagnosis: Major Application of Digital Pathology Systems
Telepathology Experiences Strong Growth
Pharmaceutical and Biotechnology Companies: Important End Use
Markets for Digital Pathology
EXHIBIT 3: Global Digital Pathology Systems Market by End-Use:
2020
Major Issues Hampering Adoption of Digital Pathology Systems
Competitive Landscape
EXHIBIT 4: Market Share of Leading Players in Digital Pathology
Systems Market: 2020E
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Technological Advancements Drive Adoption of Digital Pathology
Systems
Artificial Intelligence (AI) Steps in to Widen the Scope & Span
of Digital Pathology
EXIBIT: AI Spending in Healthcare & Lifesciences in US$ Million
for Years 2020 & 2025
Advantages of AI-Powered Digital Pathology
Digital Pathology Benefits Drug Discovery Process
Need for Early Diagnosis Puts Focus on Digital Pathology
Digital Pathology Systems See Fast Paced Adoption in Cancer and
Other Chronic Diseases
EXHIBIT 5: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 6: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
EXHIBIT 7: Global New Cancer Cases and Cancer-related Deaths by
Cancer Site (in %) for 2018
Digital Pathology Emerges as a Tool to Reduce Cases of Cancer
Misdiagnoses
Scarcity of Pathologists & Excess Workload on Pathology Labs
Drives Demand for Digital Systems
Clinical Research Continues to be Core Vertical for Digital
Pathology
Digital Imaging and Robotic Light Microscopy Boost Growth
Computational Pathology for Leading-Edge Image Analytics
Cloud Platform Gains Momentum
Telepathology Expected to Pave Way for Pathology Outsourcing to
Developing Nations
Rise in Significance of Personalized Medicine Bodes Well for
Digital Pathology
EXHIBIT 8: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024
Increased Focus on Companion Diagnostics to Benefit Market Growth
Improving Healthcare & Research Expenditure to Support Growth
EXHIBIT 9: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Aging Population: A Key Opportunity Indicator
EXHIBIT 10: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030
EXHIBIT 11: Global Population of 65+ Individuals as % of Total
Population by Region for 2019 and 2030
EXHIBIT 12: Global Cancer Deaths by Age Group (in %) for 2019
Challenges Facing Digital Pathology Systems Market
High Costs
Workflow Integration with Other Related Functions
Other Issues
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Digital Pathology
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Digital Pathology Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 3: World 12-Year Perspective for Digital Pathology
Systems by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2015,
2020 & 2027
Table 4: World Current & Future Analysis for Device by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Device by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 and
% CAGR
Table 6: World 12-Year Perspective for Device by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027
Table 7: World Current & Future Analysis for Software by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Software by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 and
% CAGR
Table 9: World 12-Year Perspective for Software by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027
Table 10: World Current & Future Analysis for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 12: World 12-Year Perspective for Other Segments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027
Table 13: World Current & Future Analysis for Human Pathology
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for Human Pathology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 15: World 12-Year Perspective for Human Pathology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027
Table 16: World Current & Future Analysis for Veterinary
Pathology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Veterinary Pathology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 18: World 12-Year Perspective for Veterinary Pathology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027
Table 19: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 21: World 12-Year Perspective for Pharma & Biotech
Companies by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027
Table 22: World Current & Future Analysis for Hospitals &
Reference Labs by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Hospitals & Reference Labs
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 24: World 12-Year Perspective for Hospitals & Reference
Labs by Geographic Region – Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2015, 2020 & 2027
Table 25: World Current & Future Analysis for Academic &
Research Institutes by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 26: World Historic Review for Academic & Research
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2015 through 2019 and % CAGR
Table 27: World 12-Year Perspective for Academic & Research
Institutes by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027
III. MARKET ANALYSIS
UNITED STATES
COVID-19 Triggers Demand for Digital Pathology
Market Overview
Increasing Pressure on Pathological Labs: Cornerstone for Growth
Table 28: USA Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for Digital Pathology Systems by
Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 30: USA 12-Year Perspective for Digital Pathology Systems
by Segment – Percentage Breakdown of Value Sales for Device,
Software and Other Segments for the Years 2015, 2020 & 2027
Table 31: USA Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 32: USA Historic Review for Digital Pathology Systems by
Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 33: USA 12-Year Perspective for Digital Pathology Systems
by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 34: USA Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 35: USA Historic Review for Digital Pathology Systems by
End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 36: USA 12-Year Perspective for Digital Pathology Systems
by End-Use – Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Hospitals & Reference Labs and Academic &
Research Institutes for the Years 2015, 2020 & 2027
CANADA
Table 37: Canada Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 38: Canada Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 39: Canada 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 40: Canada Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 41: Canada Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 42: Canada 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 43: Canada Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 44: Canada Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 45: Canada 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
JAPAN
Market Overview
Table 46: Japan Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 47: Japan Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 48: Japan 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 49: Japan Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 50: Japan Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 51: Japan 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 52: Japan Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 53: Japan Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 54: Japan 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
CHINA
Market Overview
Table 55: China Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 56: China Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 57: China 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 58: China Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 59: China Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 60: China 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 61: China Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 62: China Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 63: China 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
EUROPE
Market Overview
Table 64: Europe Current & Future Analysis for Digital
Pathology Systems by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 65: Europe Historic Review for Digital Pathology Systems
by Geographic Region – France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Thousand for Years 2015 through 2019 and %
CAGR
Table 66: Europe 12-Year Perspective for Digital Pathology
Systems by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2015, 2020 & 2027
Table 67: Europe Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 68: Europe Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 69: Europe 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 70: Europe Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 71: Europe Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 72: Europe 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 73: Europe Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 74: Europe Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 75: Europe 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
FRANCE
Table 76: France Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 77: France Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 78: France 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 79: France Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 80: France Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 81: France 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 82: France Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 83: France Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 84: France 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
GERMANY
Table 85: Germany Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 86: Germany Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 87: Germany 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 88: Germany Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 89: Germany Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 90: Germany 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 91: Germany Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 92: Germany Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 93: Germany 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
ITALY
Table 94: Italy Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 95: Italy Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 96: Italy 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 97: Italy Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 98: Italy Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 99: Italy 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 100: Italy Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 101: Italy Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 102: Italy 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027
UNITED KINGDOM
Table 103: UK Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 104: UK Historic Review for Digital Pathology Systems by
Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 105: UK 12-Year Perspective for Digital Pathology Systems
by Segment – Percentage Breakdown of Value Sales for Device,
Software and Other Segments for the Years 2015, 2020 & 2027
Table 106: UK Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 107: UK Historic Review for Digital Pathology Systems by
Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 108: UK 12-Year Perspective for Digital Pathology Systems
by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 109: UK Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 110: UK Historic Review for Digital Pathology Systems by
End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR
Table 111: UK 12-Year Perspective for Digital Pathology Systems
by End-Use – Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Hospitals & Reference Labs and Academic &
Research Institutes for the Years 2015, 2020 & 2027
SPAIN
Table 112: Spain Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 113: Spain Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 114: Spain 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027
Table 115: Spain Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 116: Spain Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR
Table 117: Spain 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027
Table 118: Spain Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 119: Spain Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05205340/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Artificial Intelligence
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
TARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer, in the 2024 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. Other top prizes went to projects in second-order cone programming, microplastics filtration and multi-sensory therapy for dementia.
The top winners were honored during two award ceremonies: the Special Awards on May 16 and the Grand Awards Ceremony on the morning of May 17. In total, over $9 million USD was awarded to the finalists based on their projects’ creativity, innovation and depth of scientific inquiry. The competition featured nearly 2,000 young scientists representing 49 U.S. states and nearly 70 countries, regions and territories across the world.
Grace Sun, 16, of Lexington, Kentucky, won first place and received the $75,000 George D. Yancopoulos Innovator Award for her research on building a better organic electrochemical transistor that she hopes will be used to develop new electronic devices that could help detect and treat serious illnesses like diabetes, epilepsy and organ failure. To overcome the problems that have previously prevented such devices from working effectively inside the body, Grace developed a new way of chemically treating their organic components, which greatly improved their laboratory performance.
Michelle Wei, 17, of San Jose, California, received one of two Regeneron Young Scientist Awards of $50,000 for her research to improve the speed and efficiency of a type of software that is useful in many fields such as machine learning, transportation and financial systems. Michelle’s new approach involved determining a quick approximate solution to the second-order cone programming problem, then splitting the initial cone into smaller cones, which enabled her new algorithm to greatly outperform previous approaches.
Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award of $50,000 for his machine-learning research to identify microbial genetic sequences that can be modified to biodegrade plastic. His new software, called Microby, scans databases of microorganisms and determines which ones can be changed genetically to biodegrade plastics. In tests, he identified two microorganisms that can be genetically modified to degrade plastic at a cost he believes would be ten times less than traditional recycling.
“Congratulations to the Regeneron International Science and Engineering Fair 2024 winners,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I’m truly inspired by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have shown that it is possible to come together in unity to tackle some of the toughest challenges facing our world today, and I could not be prouder.”
Regeneron ISEF provides a global stage for the world’s best and brightest young scientists and engineers. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025.
“The talent, intelligence and potential of this year’s Regeneron ISEF finalists is truly inspiring, and I congratulate each on their remarkable achievements,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Science competitions like ISEF were pivotal in shaping my own career and fueling my passion to fight back against disease. I look forward to seeing these students continue to push the boundaries of science and technology to create positive and sustainable change for all humanity.”
Other top honors from the competition include:
Justin Huang and Victoria Ou, both 17, of Woodlands, Texas, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for their new prototype filtration system that uses ultrasonic waves to remove microscopic plastic particles from water. In lab tests, the acoustic force from the high-frequency sound waves removed between 84% and 94% of the suspended microplastic particles in a single pass. The students are now working to scale up and fine-tune their experimental system.
Ingrid Wai Hin Chan, 17, of Hong Kong, China received the Craig R. Barrett Award for Innovation of $10,000 for her research on using a multi-sensory therapy for dementia patients. Her mixed therapy app would allow patients to practice physical and cognitive skills through a personalized, immersive environment using virtual reality headsets. Ingrid conducted an eight-week study with six people living with dementia and found that the cognitive function of patients who used her prototype improved in several areas. She believes her app could serve as a viable option for dementia patients with limited access to in-person professional therapy.
Tanishka Balaji Aglave, 15, of Valrico, Florida, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for her investigation into a natural alternative treatment against citrus greening, a disease that threatens citrus farming in many parts of the world and is currently only treated with antibiotics. Tanishka injected the trunks of infected trees with an extract from the curry leaf tree, and found through tests that this potential method could effectively and sustainably manage citrus greening disease.
Maddux Alexander Springer, 18, of Honolulu, Hawaii, received the Peggy Scripps Award for Science Communication of $10,000 for his research into fibropapillomatosis (FP), a disease that is the primary cause of death in green sea turtles. Some turtles he studied in Kaneohe Bay, Hawaii, were stricken with a disease that causes internal and external tumors that inhibit their everyday lives. After analyzing the turtles’ diet of green algae, Maddux concluded that this disease, wastewater, invasive algae and the amino acid arginine all pose a grave risk to these endangered sea creatures.
Ria Kamat, 17, of Hackensack, New Jersey; Anna Oliva, 17, of Houston, TX; and Shuhan Luo, 18, of Worcester, MA, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.
Jack Shannon, 18, of Clane, Kildare, Ireland, and Nikhil Vemuri, 17, of Cary, North Carolina, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Katowice, Poland.
For more information about the top winners and access to visual assets visit: https://www.societyforscience.org/isef-2024-media-kit.
The full list of Special Award ISEF 2024 Finalists can be found at https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners.
In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including “First Award” winners, who each received a $5,000 prize.
The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:
Animal Sciences, sponsored by Society for ScienceMaddux Alexander Springer, Honolulu, Hawaii
Behavioral and Social Sciences, sponsored by Society for ScienceAndrew Y. Liang, San Jose, California
Biochemistry, sponsored by RegeneronAmy Hong Xiao, Garden City, New York
Biomedical and Health Sciences, sponsored by RegeneronRia Kamat, Hackensack, New Jersey; Kevin Xuan Lei, Shanghai, China
Biomedical Engineering, sponsored by Alfred E. Mann CharitiesAyush Garg, Dublin, California; Divij Motwani, Palo Alto, California; Akash Ashish Pai, Portland, Oregon
Cellular and Molecular Biology, sponsored by RegeneronLara and Maya Sarah Hammoud, Beverly Hills, Michigan
Chemistry, sponsored by Society for ScienceAkilan Sankaran, Albuquerque, New Mexico; Arjun Suresh Malpani and Siddharth Daniel D’costa, Portland, Oregon
Computational Biology and Bioinformatics, sponsored by RegeneronKun-Hyung Roh, Bronx, New York
Earth and Environmental Sciences, sponsored by Google.orgNikhil Vemuri, Durham, North Carolina; Justin Yizhou Huang and Victoria Ou, The Woodlands, Texas
Embedded Systems, sponsored by HPChloe Rae and Sophie Rose Filion, Welland, Ontario, Canada
Energy: Sustainable Materials and Design, sponsored by Siemens EnergyAlia Wahban, Hamilton, Ontario, Canada
Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace FoundationChiyo Nakatsuji, Bunkyoku, Tokyo, Japan; Kevin Shen, Olympia, Washington
Environmental Engineering, sponsored by JacobsKrish Pai, San Diego, California; Jack Shannon, Clane, Kildare, Ireland
Materials Science, sponsored by Howmet Aerospace FoundationGrace Sun, Lexington, Kentucky
Mathematics, sponsored by Akamai FoundationAnna Oliva, Houston, Texas
Microbiology, sponsored by Schattner FoundationMatthew Chang, Irvine, California
Physics and Astronomy, sponsored by Richard F. Caris Charitable Trust IIHarini Thiagarajan and Vishal Ranganath Yalla, Bothell, Washington; Shuhan Luo, Worcester, Massachusetts
Plant Sciences, sponsored by Society for SciencePauline Estrada, Fresno, California; Tanishka Balaji Aglave, Dover, Florida
Robotics and Intelligent Machines, sponsored by RegeneronMichal Lajciak, Dubnica nad Vahom, Trenciansky kraj, Slovakia; Anthony Efthimiadis, Oakville, Ontario, Canada
Systems Software, sponsored by MicrosoftMichelle Wei, San Jose, California
Technology Enhances the Arts, sponsored by Society for ScienceAnant Khandelwal, Sritan Motati and Siddhant Sood, Alexandria, Virginia
Translational Medical Science, sponsored by RegeneronZheng-Chi Lee, West Lafayette, Indiana; Ingrid Wai Hin Chan, Hong Kong, China
The full list of all award-winning ISEF 2024 finalists is available here: https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards.
View all the finalists’ research here: https://projectboard.world/isef.
About the Regeneron International Science and Engineering FairThe Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science for over 70 years, is the world’s largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.
In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, including Akamai Foundation, Alfred E. Mann Charities, Aramco, Caltech, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, , Jacobs, King Abdulaziz & his Companions Foundation for Giftedness and Creativity, Microsoft, National Geographic Society, Richard F. Caris Charitable Trust II, Rise, an initiative of Schmidt Futures and the Rhodes Trust, Schattner Foundation, Siemens Energy, Annenburg Foundation, Ballmer Group, Broadcom Foundation, Cesco Linguistic Services, Conrad N. Hilton Foundation, Edison International, Insaco, Oracle Academy, The Eli and Edythe Broad Foundation, The Ralph M. Parsons Foundation and US Army ROTC. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.
About Society for ScienceSociety for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
More information about the top winners and access to visual assets visit: https://www.societyforscience.org/isef-2024-media-kit.
Media ContactsJoseph Brown, [email protected]
Gayle Kansagor, Society for [email protected]
Photo – https://mma.prnewswire.com/media/2416174/Regeneron_ISEF_2024_Winners_Photo.jpg
Logo – https://mma.prnewswire.com/media/2416197/Society_for_Science_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-302149316.html
Artificial Intelligence
J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit
In conjunction with Abu Dhabi Global Healthcare Week 2024
ABU DHABI, UAE, May 17, 2024 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group announced today Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.
In partnership with the Department of Health – Abu Dhabi (DoH), the Summit took place on May 14-15, 2024 at Cleveland Clinic Abu Dhabi and showcased the 11 innovative finalists, as well as highlighted existing innovators and opportunities in the Emirate of Abu Dhabi. The event also featured keynote speeches from Dr. Laurie Glimcher of Dana-Farber Cancer Institute, Dr. Shahrukh Hashmi of the Department of Health – Abu Dhabi, and Dr. David Ho of Columbia University Medical Center and provided attendees networking opportunities to gain valuable insights into the future of life sciences innovation.
In addition, the jury designated Chun-Hao Huang of Algen Biotechnologies as honourable mention. Algen Biotechnologies is a platform therapeutics and drug discovery company using world-leading CRISPR and AI to find treatments for cancer, inflammation and metabolic diseases.
The winners were selected by an esteemed, international panel of judges, which included:Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman, MD, CEO at Cleveland Clinic Abu DhabiProf. Shahrukh Khurshid Hashmi, MD, Director of Research, Department of Health, Abu DhabiYasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess, Managing Partner at J.P. Morgan Life Sciences Private CapitalWalid Zaher, PhD, Co-Founder and CEO, Carexso
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi said: “Under the directives of the UAE’s wise leadership, and renowned for its world-leading medical infrastructure, Abu Dhabi stands at the forefront of healthcare excellence, offering an unparalleled opportunity for advancement in healthcare for global partners. It was our utmost pleasure hosting the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week and we commend the winners for their pioneering efforts in driving impactful advancements in healthcare; their dedication to innovation not only transforms the landscape of medicine, but also holds the promise of improving lives worldwide.”
Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are thrilled with the level of biotech passion and innovation that we observed at this year’s Summit in Abu Dhabi. The energy was truly palpable we are thrilled to announce Rayees Rahman as the winner of our first Life Sciences Innovation Summit. Harmonic Discovery’s approach embodies the next generation of drug discovery and development. We appreciate the time and effort of all participants and cannot wait for our next event in the region.”
Nabil Kobeissi, Chief Executive Officer of Blue Horizon Advisors, said: “As the main sponsor, we are committed to nurturing and fostering the growth of all 11 finalists in this vibrant biotech ecosystem. This Summit marks the beginning of a transformative journey, and we are confident that it will pave the way for a flourishing hub in the region. We are also pleased to announce that we will commit to invest in and partner with the winner, Harmonic Discovery, to support its future growth in the region.”
Sponsors for the event included J.P. Morgan Life Sciences Private Capital, J.P. Morgan Commercial Bank, Blue Horizon Advisors, United Al Saqer Group, Thermo Fisher Scientific, and Salam Capital. The Summit organisation, logistics and finalist recruitment were facilitated by Lyfebulb.
Of importance, at the Summit, Mr. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, announced that Masdar City Free Zone would award all 11 Finalists complimentary business licenses to further support their establishment in the region. Masdar City is one of the world’s most sustainable urban developments and innovation hubs with a growing focus on life science entrepreneurship in Abu Dhabi.
View original content:https://www.prnewswire.co.uk/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit-302149186.html
Artificial Intelligence
Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024
SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.
Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html
-
Uncategorized5 days agoCrossover Markets Becomes First Crypto ECN to Integrate with Talos
-
Uncategorized5 days ago
Precisely Showcases Critical Role of Trusted Data in AI at the Gartner® Data & Analytics Summit in London
-
Artificial Intelligence5 days agoMSI Highlights Optimized AI Platforms to Accelerate Compute-Intensive Applications at ISC 2024
-
Artificial Intelligence4 days agoAdvanced HPC Server Platforms by MiTAC and TYAN Spotlighted at ISC High Performance 2024
-
Uncategorized3 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence7 days agoElevate Your Virtual Reality Experience with KIWI design RGB Vertical Stand, Now Available on Meta’s Website
-
Artificial Intelligence5 days agoLG CEO EMBARKS ON STRATEGIC U.S. VISIT TO ENHANCE AI INITIATIVES
-
Artificial Intelligence5 days ago
Supermicro’s Rack Scale Liquid-Cooled Solutions with the Industry’s Latest Accelerators Target AI and HPC Convergence
